OPK — OPKO Health, Inc.

OPKO Health Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $148.5 million, down from $183.6 million in Q4 2024, primarily due to the divestiture of oncology assets.
• Diagnostics Revenue: $71.1 million, including $7 million from the 4Kscore test (up 16% year-over-year).
• Pharmaceutical Revenue: $77.4 million, a slight decline from $80.5 million in the prior year.
• Operating Loss: $38.3 million, compared to a loss of $33.1 million in Q4 2024.
• Net Loss: $31.3 million, or $0.04 per share, compared to a net income of $14 million in Q4 2024.
• Cash Position: $369 million, allowing for continued R&D investment and share repurchases totaling over $109 million in 2025.

2. Strategic Updates and Business Highlights

• Diagnostics Transformation: Completed the sale of oncology assets to Labcorp, focusing BioReference on core clinical laboratory services and the 4Kscore test.
• ModeX Pipeline: Advancements in multiple clinical-stage programs, including an EBV vaccine partnered with Merck and several immuno-oncology candidates.
• Regeneron Collaboration: A significant partnership with potential milestones exceeding $1 billion, focusing on metabolism, oncology, and immunology.
• International Pharmaceutical Sales: Grew by 17% year-over-year, contributing positively to cash flow.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $125 million and $140 million, with service revenue of $71 million to $75 million.
• Full Year 2026 Revenue Guidance: Projected total revenue of $530 million to $560 million, with pharmaceutical product revenue of $160 million to $170 million.
• R&D Investment: Expected to be between $125 million and $135 million for the full year, supported by BARDA funding.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant decrease in total revenue is attributed to the Labcorp transaction, which may impact growth trajectories.
• Operating Losses: Continued operating losses in both diagnostics and pharmaceuticals raise concerns about profitability.
• Dependence on Partnerships: The reliance on collaborations for funding and revenue generation, particularly with Regeneron and BARDA, introduces risks if these partnerships do not yield expected results.
• Market Competition: The company faces competitive pressures in both diagnostics and therapeutic segments, which could affect market share and pricing strategies.

5. Notable Q&A Insights

• MDX2001 and MDX2004 Updates: Management indicated that results from MDX2001's Phase I trial will be shared by the end of 2026, with plans to enter Phase Ib. MDX2004 is positioned as an immune rejuvenator with broad potential applications.
• 4Kscore Test Growth: Current growth is driven by urology, with expectations for acceleration as payer coverage improves.
• Merck Partnership: The Phase II trials for the EBV vaccine are anticipated to begin next year, pending additional data from ongoing studies.
• Regeneron Collaboration: The partnership is expected to provide significant funding and support for multiple programs, with milestones that could enhance OPKO's financial position.

Overall, OPKO Health is navigating a transformative period with strategic divestitures and partnerships, but faces challenges in revenue stability and profitability. The outlook for 2026 includes cautious optimism driven by ongoing clinical developments and operational efficiencies.